JNJ vs MAR: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-20.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$366.24
-3.4% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
MAR has more upside to fair value
(-3.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
MAR |
| Current Price |
$253.85 |
$366.24 |
| Fair Value Estimate |
$198.76 |
$353.64 |
| Upside to Fair Value |
-21.7%
|
-3.4%
|
| Market Cap |
$611.1B |
$96.6B |
| Forward P/E |
29.3x
|
—
|
| EV / EBITDA |
19.2x
|
23.8x
|
| Price / Sales |
6.3x
|
3.7x
|
| Price / FCF |
34.3x
|
31.6x
|
| Revenue Growth YoY |
+9.9%
|
+6.2%
|
| Gross Margin |
69.1%
|
21.4%
|
| Operating Margin |
26.9%
|
16.0%
|
| Return on Equity |
26.3%
|
-74.1%
|
| Dividend Yield |
0% |
0.75% |
| FCF Yield |
2.91%
|
3.17%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Marriott International is a global asset-light hotel franchisor, manager and licensor whose high-quality brands, nearly 283 million Bonvoy members, more than 9,900 properties across 146 countries and record 4,107-property development pipeline create meaningful network, distribution and brand advantages. Q1 2026 demonstrated resilient underlying fee economics: adjusted revenue excluding cost-reimb…
Accumulation Zones
| Metric |
JNJ |
MAR |
| Zone Low |
$149.07 |
$265.23 |
| Zone High |
$168.95 |
$300.59 |
| In Buy Zone? |
No
|
No
|